Monday, January 12, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Sell Rating on Stellus Capital Investment with Lower Price Target

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

On March 6, 2024, Bryce Rowe, an analyst at B. Riley Securities, reaffirmed his Sell rating on Stellus Capital Investment (NYSE: SCM) and adjusted the price target to $12.50, down from $13. This update comes after Stellus Capital Investment was downgraded from Neutral to Sell by B. Riley, citing a changing market environment. The previous price target of $13 has been revised in light of these developments.

SCM Stock Performance Shows Interesting Movements on March 6, 2024

On March 6, 2024, SCM’s stock performance showed some interesting movements. According to data from CNN Money, SCM was trading near the bottom of its 52-week range and below its 200-day simple moving average. This indicates that the stock may be experiencing some downward pressure.

However, on that particular day, there was a slight uptick in the price of SCM shares. The stock had increased by $0.22 since the market last closed, representing a 1.73% rise. This brought the closing price of SCM shares to $12.97.

Despite this initial increase, the stock experienced a drop of $0.09 in pre-market trading. This drop may have been influenced by various factors such as market sentiment, economic indicators, or company-specific news.

SCM Stock Performance Analysis: Revenue Decline and Net Loss Raise Concerns for Investors

On March 6, 2024, SCM stock experienced a mixed performance based on the latest financial data provided by CNN Money. The company’s total revenue for the past year was $78.77 million, a decrease of 9.86% compared to the previous year. However, the total revenue for the third quarter was $27.77 million, showing an increase of 5.67% from the previous quarter.

In terms of net income, SCM reported a net income of $14.49 million for the past year, which represents a significant decrease of 56.83% compared to the previous year. The net income for the third quarter was -$2.40 million, indicating a loss for that period and a decrease of 164.6% from the previous quarter.

Earnings per share (EPS) also saw a decline for SCM stock. The EPS for the past year was $0.74, a decrease of 56.97% compared to the previous year. The EPS for the third quarter was -$0.10, showing a loss per share and a decrease of 160.07% from the previous quarter.

Overall, these financial indicators suggest that SCM stock has faced challenges in terms of revenue, net income, and earnings per share. Investors may be concerned about the company’s performance and future prospects based on these figures. It is important for investors to closely monitor SCM’s financial performance and any updates from the company to make informed decisions about their investments in the stock.

Tags: SCM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Stock Market Today (1)

Harvard Bioscience Inc Unveils CuttingEdge Product Advancements for Research at SOT Conference

The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

BTIG Analyst Gray Powell Optimistic about HashiCorps Future Growth

Groundbreaking Clinical Study Shows Effectiveness of AVIM Therapy in Hypertensive Pacemaker Patients

Recommended

Upcoming FDA Advisory Committee Meeting for Imetelstat A Groundbreaking Treatment for Malignant Stem Cells

2 years ago
Portillo's Stock

Leadership Turmoil Sends Portillo’s Shares to New Low

2 months ago
Dine Brands Global Stock

Dine Brands Stock Faces Potential Downturn

1 month ago
Intel Stock

US Government Considers Taking Equity Stake in Intel

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs

Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

Procter & Gamble Shares Approach a Critical Juncture

Trending

XRP Stock
Analysis

XRP Market Dynamics: Institutional Pause Meets Accumulation Surge

by Andreas Sommer
January 11, 2026
0

The XRP market is currently defined by a stark divergence in investor behavior. After a powerful rally...

Rocket Lab USA Stock

Rocket Lab’s Stock Momentum Continues Unabated in 2026

January 11, 2026
Eli Lilly Stock

Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

January 11, 2026
Alibaba Stock

Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs

January 11, 2026
Vulcan Energy Stock

Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

January 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • XRP Market Dynamics: Institutional Pause Meets Accumulation Surge
  • Rocket Lab’s Stock Momentum Continues Unabated in 2026
  • Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com